|
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
13 December 2019 |
|
Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
13 December 2019 |
|
Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors
|
12 December 2019 |
|
Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
|
11 December 2019 |
|
Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement
|
11 December 2019 |
|
Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
|
10 December 2019 |
|
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
|
09 December 2019 |
|
Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting
|
06 December 2019 |
|
Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting
|
27 November 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
08 November 2019 |
|
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results
|
06 November 2019 |
|
Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer
|
29 October 2019 |
|
Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting
|
17 October 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
27 September 2019 |
|
Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
|
26 September 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
23 August 2019 |
|
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
|
08 August 2019 |
|
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
|
23 July 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
|
19 June 2019 |
|
Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
|
03 June 2019 |
|
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
|
01 May 2019 |
|
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
|
11 March 2019 |
|
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
|
06 March 2019 |
|
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
|
05 March 2019 |
|
Marinus Announces Leadership Transition
|
26 February 2019 |
|
Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference
|
20 February 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
05 February 2019 |
|
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
25 January 2019 |
